Introduction
In a classical G-protein-coupled receptor (GPCR) signaling pathway, GPCRs directly relay the signals by activating heterotrimeric guanine nucleotide binding regulatory proteins (G proteins) (Gilman, 1987) . Based on sequence homologies and functional similarities of their a subunits, these G proteins are grouped into four families: G s , G i , G q , and G 12 (Simon et al, 1991) . Src-family tyrosine kinases are another major group of cellular signal transducers and have been demonstrated to directly relay signals from membrane receptors (Thomas and Brugge, 1997) . Many GPCRs are able to increase the activity of Src-family tyrosine kinases (Chen et al, 1994; Ishida et al, 1995; Ptasznik et al, 1995; Luttrell et al, 1996; Rodriguez-Fernandez and Rozengurt, 1996; Schieffer et al, 1996; Wan et al, 1996 Wan et al, , 1997 Ma et al, 2000; Luttrell and Luttrell, 2004) . Some of the documented GPCR-induced events that involve tyrosine kinases include the activation of mitogen-activated protein kinase (MAPK) cascades (Chen et al, 1994; Luttrell et al, 1996; Simonson et al, 1996; Wan et al, 1996 Wan et al, , 1997 Schieffer et al, 1997) .
For the Gs-coupled b 2 -adrenergic receptors (b 2 -ARs), c-Src has been shown to act downstream of Gs to mediate b 2 -AR activation of ERK MAPK (the extracellular signal-regulated kinase subfamily of MAPKs) in some cell types. The molecular mechanisms by which c-Src participates in these pathways seem to differ, depending on cell types and even clonal variants of the same cell type (Lefkowitz et al, 2002) . For example, in HEK-293 cells, it was reported that, after ligand stimulation of transfected b 2 -AR, b-arrestin formed a complex with Src and brought Src to the b 2 -AR, leading to receptor desensitization/internalization, which initiates a second wave of signaling including the ERK MAPK pathway (Luttrell et al, 1999) . It was also suggested that, after b 2 -AR activation of Gs and adenylyl cyclase (AC), PKA phosphorylated b 2 -AR and enhanced b 2 -AR's coupling to Gi protein.
The Gbg subunits released from Gi activated Src leading to Ras/c-Raf1/MEK/ERK activation (Daaka et al, 1997) . On the other hand, other groups have reported that endogenous or transfected b 2 -ARs, via Ga s activation of PKA, Rap1, and B-Raf, stimulated ERK in an Src-dependent and PTX (pertussis toxin)-insensitive manner Stork, 2000, 2002a; Friedman et al, 2002) . This discrepancy of results from HEK-293 cells was later attributed to the possible uses of different variants of HEK-293 cell lines (Lefkowitz et al, 2002) . In other cell types such as CHO cells, PC12 cells, and NIH3T3 cells, the activation of ERK by Gs-coupled receptors seemed also to involve Gs, PKA, and Src proteins (Klinger et al, 2002) . Furthermore, for the Gs-coupled b 3 -AR, it was reported that c-Src and b 3 -AR were co-immunoprecipitated in an agonist-dependent and PTX-sensitive manner (Cao et al, 2000) . It was suggested that b 3 -AR activated Gi, which activated c-Src. Activated c-Src was then recruited to b 3 -AR by binding to b 3 -AR (Cao et al, 2000) .
In the above studies, the activation of c-Src by b 2 -AR is G-protein-dependent. During our study of ERK activation by b 2 -ARs in Ga s À/À mouse embryonic fibroblast (MEF) cells, we noticed that there is a G-protein-independent pathway. We have pursued this G-protein-independent signaling in this current study. Although GPCRs are known to transduce signals through G proteins, there are indications that these receptors are also able to signal in a G-protein-independent manner (Milne et al, 1995; Ali et al, 1997; Brakeman et al, 1997; Sexl et al, 1997; Araki et al, 1998; Hall et al, 1998; Jin et al, 1998; Cao et al, 2000; Miller and Lefkowitz, 2001; Seta et al, 2002; Whistler et al, 2002; Bockaert et al, 2004; Shenoy et al, 2006; Wang et al, 2006) . However, the mechanistic relationship between the G-protein-dependent and the G-protein-independent signaling by GPCRs, and the biochemical mechanism by which GPCRs initiate G-protein-independent signaling have not been elucidated. Here, we use the activation of the ERK MAPK pathway in MEF cells as a model system to investigate G-protein-dependent and -independent signaling by GPCRs. The reason for using MEFs was to take advantage of the availability of specific gene-knockout MEF cells. We found that the response of MAPK to stimulation by b 2 -AR is biphasic. While the first phase of this response is abolished in Ga s -deficient cells, deletion of Srcfamily tyrosine kinases eliminates the second phase. Furthermore, b 2 -AR can directly activate Src, independent of Ga s and b-arrestins. Thus, the receptor signals are transduced through two mechanisms with agonist dosage acting as the switch.
Results
Biphasic dose-response of b 2 -AR activation of ERK MAPK In MEF cells, stimulation with isoproterenol, an agonist for b 2 -AR, increased the kinase activity of ERK MAPK ( Figure 1A ). The dose-response curve of this stimulation was better fitted with a two-site competition equation than with a one-site competition equation, indicating the existence of two distinct phases of b 2 -AR signaling ( Figure 1B) . The EC 50 of isoproterenol for the first phase was B1 nM and the EC 50 for the second phase was B1 mM. Pre-treatment of MEF cells with selective b 2 -AR antagonist ICI-118551 (1 mM) blocked the stimulation of ERK MAPK (both phases) by isoproterenol ( Figure 1B ). This biphasic dose-response of isoproterenol activation of ERK MAPK had been observed before in COS-7 cells, although it was not discussed and explored further (Crespo et al, 1995) . Furthermore, we established a CHO cell line stably expressing b 2 -AR. In these cells, the dose-response curve of b 2 -AR activation of ERK was also biphasic ( Figure 1C and D) . Although there might be other explanations for this biphasic dose-response curve of b 2 -AR activation of ERK MAPK, the simplest explanation is that b 2 -AR signals through two different signaling pathways: at low concentrations (oB100 nM) of isoproterenol, b 2 -AR signals through one pathway; at high concentrations (4B100 nM), b 2 -AR triggers an additional pathway.
Ga s is responsible for the first phase of the response As Ga s is known to mediate b 2 -AR signaling to ACs to produce cAMP, we first investigated the role of Ga s in this biphasic dose-response. In MEF cells, isoproterenol increased the cellular cAMP levels with an EC 50 of B30 nM ( Figure 1E ). This EC 50 value is closer to the EC 50 of the first phase of the biphasic dose-response, implying that Ga s might be responsible for the first response phase. To examine the role of Ga s , we used a genetic approach by studying isoproterenol stimulation of ERK MAPK activity in Ga s À/À MEF cells (Bastepe et al, 2002 ). In Ga s À/À cells, isoproterenol was unable to increase the cellular cAMP levels, confirming the functional absence of Ga s ( Figure 1F ). On the other hand, forskolin (directly activating ACs) increased cAMP in Ga s À/À cells ( Figure 1G ). When ERK MAPK activity was examined, the first phase of the dose-response curve of isoproterenol stimulation of ERK MAPK was absent whereas the second phase was almost intact with an EC 50 of 10 mM ( Figure 1H and I The second phase of the response requires b-ARs We then focused on the signaling pathway that is responsible for the second phase of the dose-response curve. First, we asked whether this response is still through b 2 -AR. In
at low and high concentrations, was unable to increase cellular cAMP levels ( Figure 2A ). However, b 1
gave rise to increased cAMP levels in response to forskolin ( Figure 2B ). Furthermore, in b 1
low and high concentrations did not activate ERK MAPK ( Figure 2C ). These data demonstrate that isoproterenol at the concentrations that we used here still acts through b-ARs. These data validate that the second phase of the response is still a b-AR-mediated event.
Neither Ga i nor b-arrestins mediate the second phase of the response Next, we examined the signaling molecules downstream of b 2 -AR that are directly responsible for the second phase of the dose-response curve. In in vitro reconstitution studies, it was shown that b 2 -AR was also capable of coupling to Ga i (Cerione et al, 1985; Rubenstein et al, 1991) . To study a possible role of Ga i in the second phase, we treated Ga s À/À cells with PTX, a toxin that would inhibit Ga i , and then measured the dose-response of isoproterenol stimulation of ERK MAPK. As shown in Figure 2D and E, PTX treatment had no effect on the EC 50 (B10 mM) of Ga s À/À cells. Under similar experimental conditions, PTX blocked the stimulation of ERK MAPK by Gi-coupled m2 muscarinic acetylcholine receptors ( Figure 2F ). Furthermore, expression of RGS4 (a GAP for Ga q and Ga i proteins) and the RGS-like domain of p115 Rho-GEF (a GAP for Ga 12 and Ga 13 proteins) in Ga s À/À cells did not affect the ERK activation by 10 mM of isoproterenol ( Figure 2G ). These data rule out a primary role for heterotrimeric G proteins in the second phase of ERK MAPK activation by isoproterenol. It has been postulated that b 2 -AR, after internalization, could initiate a second wave of signaling events including the activation of ERK MAPK (Luttrell et al, 1999) . Therefore, we examined whether b 2 -AR internalization is responsible for the second phase. b-Arrestin 2 has been shown to be absolutely required for b 2 -AR internalization in MEF cells (Kohout et al, 2001; Huang et al, 2004) . Src tyrosine kinase is required for the second phase of the response Src tyrosine kinase has been shown to mediate b 2 -AR cellular signaling at several levels (Luttrell et al, 1999; Ma et al, 2000; Schmitt and Stork, 2002b) . Therefore, we turned our attention to Src for a possible role in transducing the second phase of the isoproterenol stimulation of ERK MAPK. In Src-family tyrosine kinase-deficient SYF cells, low concentrations of isoproterenol increased the ERK MAPK activity with an EC 50 of B30 nM ( Figure 3A 
and B). (SYF cells are MEF cells derived from Src
Remarkably, high concentrations of isoproterenol did not further increase the ERK MAPK activity ( Figure 3A and B). This defect was due to the absence of Src-family tyrosine kinases as re-expression of c-Src in SYF cells restored the biphasic response of ERK activation by isoproterenol ( Figure  3C and D). The EC 50 for isoproterenol increasing cellular cAMP in SYF cells was also B30 nM ( Figure 3E ), a value that is same as that in wild-type MEF cells. Furthermore, the ERK activation in Ga s À/À cells by 100 mM isoproterenol was abolished by 10 mM PP2, an Src-family tyrosine kinase inhibitor ( Figure 1I ). Moreover, from radio-ligand binding experiments, SYF cells had a similar b 2 -AR density on the membrane as wild-type MEFs. SYF cells possess 0.4470.09 pmol/ mg of membrane protein (n ¼ 3), whereas wild-type MEF cells have 0.5570.11 pmol/mg of membrane protein (n ¼ 3). These genetic data demonstrate that, in SYF cells, Ga smediated b 2 -AR signaling is intact whereas the second phase of the ERK MAPK activation was abolished. Thus, Src-family tyrosine kinases are required for the second phase of the response. 
Direct interaction of b 2 -AR with Src
Having established that Src-family tyrosine kinases are required for the second phase of the isoproterenol stimulation of ERK MAPK, we then investigated the biochemical mechanism by which b 2 -AR is connected to Src. Src has been shown to be activated by b 2 -AR signals through several mechanisms: by direct Ga s contact (Ma et al, 2000) , by PKA phosphorylation (Schmitt and Stork, 2002b) , and by b-arrestin recruitment (Luttrell et al, 1999 ). As Ga s and b-arrestin 2 are not essential for the second phase of ERK MAPK activation, there might be an additional route(s) for b 2 -AR activation of Src. We found that, in Ga s À/À cells and b-arrestin 1 À/À /b-arrestin 2 À/À cells, isoproterenol (10 mM) was still able to stimulate Src ( Figure 4A ). This finding indeed suggested that another Src activation pathway is employed by b 2 -AR in transducing the isoproterenol stimulation in the second phase of the response. Next, we performed biochemical studies with purified Src tyrosine kinase and the purified C-terminal tail (amino-acid residues 331-413) of b 2 -AR to examine whether b 2 -AR could directly interact with Src, and whether Src could directly phosphorylate b 2 -AR. First, we found that c-Src could directly interact with the C-terminal tail of b 2 -AR, and that this binding depends on the phosphorylation states of both proteins. When the C-terminal fragment of b 2 -AR (as a GST fusion protein) was unphosphorylated, purified unphosphorylated Src could bind to it ( Figure 4B ). (The purity of these recombinant proteins is shown in the bottom panel of Figure 4E .) Pre-activated Src (pre-incubation with ATP to induce autophosphorylation at Tyr-416 of the activation loop of c-Src) or Csk-inactivated Src (Tyr-527 phosphorylated by Csk) did not bind to the unphosphorylated C-terminal tail of b 2 -AR ( Figure 4C , lanes 3 and 4, and data not shown). On the other hand, pre-activated Src bound to the phosphorylated C-terminal tail of b 2 -AR ( Figure 4C, lanes 1 and 2) . Furthermore, endogenous c-Src could be co-immunoprecipitated with endogenous b 2 -AR in cells with or without isoproterenol stimulation, confirming a previous report (Fan et al, 2001 ) ( Figure 4D ). Second, we examined whether Src could directly phosphorylate the C-terminal tail of b 2 -AR. As shown in Figure 4E , purified Src was able to phosphorylate the purified C-terminal tail of b 2 -AR. Expression of a constitutively active Src in cells also led to increased phosphorylation of b 2 -AR (data not shown). Together, these data demonstrate that b 2 -AR could directly interact with Src. of direct activation of Src by b 2 -AR as b 2 -AR could directly bind to Src. We purified recombinant human b 2 -AR, c-Src, and Gb 1 g 2 proteins from Sf9 cells, and recombinant Ga s proteins from Escherichia coli ( Figure 5A ). When Src is activated, it can autophosphorylate the Tyr-416 residue. We used this increase of tyrosine autophosphorylation as a measure for Src activation. As shown in Figure 5B and C, in the absence of ATP, Src was not tyrosine phosphorylated ( Figure 5B, lane 1) . Addition of ATP led to basal Src autophosphorylation ( Figure 5B, lane 2) . In the absence of agonist or in the presence of an antagonist, b 2 -AR did not increase this basal autophosphorylation ( Figure 5B, lanes 3 and 4) . Significantly, when purified b 2 -AR was reconstituted with purified Src, addition of isoproterenol increased the extent of tyrosine phosphorylation of Src ( Figure 5B, lane 5) . This increase of Src activity by isoproterenol was blocked by pretreatment with the b 2 -AR antagonist alprenolol ( Figure 5B , lane 6). Furthermore, using GST-CDB3 fusion protein as an exogenous substrate for Src, similar results were obtained ( Figure 5D and E). These data demonstrate that b 2 -AR could directly activate Src and that Src activation by b 2 -AR is agonist-dependent.
As GPCRs activate G proteins by accelerating the rate of guanine nucleotide exchange, we further studied the biochemical mechanism by which b 2 -AR activates Src by examining the rate of Src activation by b 2 -AR. We first tested our purified b 2 -AR proteins on Gs activation ( Figure 5F ). In the presence of agonist isoproterenol, GTPgS binding to Gs (a s þ bg) was faster than in the presence of antagonist alprenolol ( Figure 5F ). The reason for adding alprenolol was to reduce the basal activity of purified b 2 -ARs. Then we examined the time course of Src activation by b 2 -AR. Similar to the activation of G proteins, b 2 -AR accelerated the rate of Src activation. In the short time points (0.5, 1, and 2 min), the degree of Src autophosphorylation in the presence of isoproterenol was higher than that in the presence of alprenolol ( Figure 5G, lanes 1-6) . However, after 4-min incubation, Src autophosphorylation with isoproterenol or alprenolol showed similar levels ( Figure 5G , bottom panel, lanes 7 and 8). Hence, b 2 -AR increases the rate of Src activation, similar to G-protein activation.
To further link the Src and b 2 -AR interaction to the second phase of the ERK activation by b 2 -AR, we have performed mutagenesis studies. We wanted to identify a b 2 -AR-mutant that would not bind to c-Src and then to examine whether b 1 À/À /b 2 À/À cells expressing this b 2 -AR-mutant would lack the second phase of the ERK response. As the C-terminal tail (residues 331-413) of b 2 -AR was sufficient for binding to c-Src and the C-terminal tail of turkey b-AR could not bind to c-Src ( Figure 6A and B), we have made several chimeras of these C-terminal tails to change some of the b 2 -AR residues to those in turkey b-AR. Among these chimeras, a b 2 -AR-mutant (named b 2 -AR-mutant-2 in Figure 6A ) was unable to bind to c-Src ( Figure 6B ). This b 2 -AR-mutant contains three aminoacid changes in the proposed helix 8 (based on the crystal structure of rhodopsin) (Palczewski et al, 2000) . As a control, an adjacent mutation (named b 2 -AR-mutant-1 in Figure 6A ) was used and shown to bind to c-Src. These b 2 -AR-mutants were made on the GST-b 2 -AR C-terminal tail (residues 331-413) backbone. Both these b 2 -AR-mutants had no defects in activating Gs, as measured by the cAMP assay in response to isoproterenol ( Figure 6C ). We then established b 1
cells stably expressing the b 2 -AR-mutant-2. In these cells, the first phase of the ERK response after isoproterenol stimulation was intact whereas the second phase of the response was absent ( Figure 6D and E). These data show that a b 2 -ARmutant defective in c-Src binding leads to the absence of the second phase of the ERK response, consistent with a role for c-Src in the second phase of the activation of ERK by b 2 -AR.
Discussion
Our new finding of the dose-dependent shift of signaling modes by a GPCR has several implications. G-protein-dependent signaling and G-protein-independent signaling are related by their different sensitivity to concentrations of the same agonist. The G-protein-dependent signaling of GPCRs is similar to receptor tyrosine kinase signaling through the small GTPase Ras. The G protein-independent signaling of GPCRs can be compared to cytokine JAK-STAT signaling, in which non-receptor tyrosine kinases are directly coupled to membrane receptors. Also, it is interesting to note that some seven-transmembrane receptors, such as Smoothened in Hedgehog gradient signaling, mainly use their C-terminal tails to directly interact with downstream signaling molecules without the participation of G proteins (Lum and Beachy, 2004) . Both the JAK-STAT and the Smoothened pathways result in activation of latent cytoplasmic transcription factors. Src could mediate GPCR-responsive changes in gene expression ( Figure 6F ). Furthermore, it is known that high-affinity agonist binding of GPCRs requires a functional interaction between the receptors and G proteins. This behavior is consistent with our observation that the G-protein-coupled signaling requires low concentrations of agonists whereas non-G-protein signaling needs high concentrations of agonists. We should point out that the maximum ERK MAPK responses at high concentrations of ligands are contributed by both Ga s -mediated and Src-mediated pathways and result in the summation of responses from both pathways. The relative contributions of the first phase and the second phase to the maximum response are approximately the same. One explanation for this observation is that b 2 -AR, at high concentrations, exists in two distinct conformations. Approximately half of the b 2 -AR population is in a conformation that is compatible with G-protein coupling, whereas the other half is in a conformation that is not compatible with G-protein-coupling. Rather, these receptors could interact with and activate Src. In this regard, it is interesting to note that purified b 2 -ARs, in the presence of high concentrations of agonist (100 mM of isoproterenol), have been shown to exist in two distinct biophysical conformations, suggesting that there is more than one active biophysical conformation for a given receptor (Swaminath et al, 2004) . We speculate that these two structurally different conformations might correspond to the two functionally different conformations that we propose here. Thus, it is possible that one agonist could induce discrete receptor conformations permitting the receptor to recognize different interacting effectors (e.g., Ga s or Src) and to activate the same or different cellular pathways. Future structural and functional (G-protein coupling versus Src coupling) investigations should shed light on this fundamental receptor property.
We propose a model for the direct activation of Src by b 2 -AR. The mechanism is similar to that of the direct activation of tyrosine kinase JAK by cytokine receptors. In this model, unphosphorylated Src (partially active) is associated with the C-terminal tail of unphosphorylated b 2 -AR in the absence of ligands. As Csk-phosphorylated c-Src could not bind to the C-terminal tail of b 2 -AR, the c-Src proteins that are constitutively associated with b 2 -ARs are likely dephosphorylated at the C-terminal tail tyrosine residue before ligand stimulation. Ligand binding of b 2 -AR leads to the activation of Src. It is speculated that high concentrations of ligands could induce b 2 -AR dimerization or cause conformational changes (or stabilization) of pre-formed b 2 -AR dimers. Although we have not examined dimerization here, there have been numerous reports of GPCR dimerization including b 2 -AR (Bouvier, 2001) . This dimerization or the conformational change (more likely) would bring two Src molecules to proximity and lead to intermolecular autophosphorylation at Tyr-416 and full activation. Activated Src could signal to downstream targets, such as the ERK MAPK pathway. Furthermore, activated Src could phosphorylate the C-terminal tail of b 2 -AR (activated Src could temporarily dissociate from, phosphorylate, and rebind b 2 -AR). These phosphorylated tyrosine residues on b 2 -AR could then serve as potential docking sites for other signaling molecules. Receptor-bound activated Src could also phosphorylate other proteins. These would lead to Ga s -independent and Src-dependent signaling pathways, contributing to the increase in ERK MAPK activity in the second phase and other physiological responses.
A Gi protein-dependent and agonist-induced co-immunoprecipitation of activated c-Src with b 3 -AR was reported previously (Cao et al, 2000) . b 3 -AR utilized a PTX-sensitive intracellular pathway to activate c-Src. This activated c-Src was recruited to b 3 -AR by interacting with the proline-rich motifs in the third intracellular loop and the C-terminal tail of b 3 -AR. It was shown that the peptides from the third intracellular loop or from the C-terminal tail of b 3 -AR could bind to GST-Src SH3/ SH2 fusion protein, but not to GST-Src SH2 fusion protein.
There are several differences in the b 3 -AR and c-Src interaction and the interaction between b 2 -AR and c-Src reported here. First, the b 2 -AR and c-Src interaction was G-protein-independent whereas the b 3 -AR and c-Src interaction was Gi-dependent. Second, b 2 -AR directly activated c-Src in vitro, in the absence of G proteins. b 3 -AR did not directly activate c-Src, instead utilized a Gi-dependent intracellular pathway to activate c-Src. Third, b 2 -AR and c-Src interaction was constitutive whereas b 3 -AR and c-Src interaction was agonist-dependent. Fourth, both inactive and active c-Src interacted with b 2 -AR whereas only activated c-Src interacted with b 3 -AR.
Our finding has a significant implication for receptor desensitization. Receptor desensitization reflects no further increase or even a decline of a physiological response in the continuous presence of ligand. Depending on the physiological responses (or readouts), the underlying biophysical basis could be different. If GPCR desensitization is defined as its uncoupling from G proteins, our data of the shift of signaling modes by increasing ligand concentrations suggest that GPCR desensitization (excluding receptor internalization and downregulation) is an intrinsic property of the receptor proteins induced by ligand binding, similar to the inactivation property of ion channel proteins. Although no auxiliary protein factors (such as GRK and arrestin proteins) are essential for this G-protein decoupling, these proteins could directly or indirectly facilitate and amplify the desensitization processes in cells (such as through receptor internalization and downregulation).
Materials and methods

Cell lines
The MEF cells deficient of Ga s (Ga s À/À cells) were derived from Ga s (exon 2) knockout mice (Bastepe et al, 2002) . The MEF cells deficient of both b 1 -AR and b 2 -AR (b 1 À/À b 2 À/À cells) were derived from b 1 -AR and b 2 -AR double knockout mouse embryos (Rohrer et al, 1999) . The MEF cells deficient of Src-family tyrosine kinases (SYF cells) were purchased from ATCC. The MEF cells deficient of b-arrestin 1 and 2 were kindly provided by Dr R Lefkowitz (Duke University) (Kohout et al, 2001) .
cAMP assay
The cAMP assay was performed as described previously (Huang et al, 2004) . Cells were plated onto six-well plates and treated with 1 mM IBMX for 30 min. After washing twice with HEM buffer (20 mM Hepes, pH 7.4, 135 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 2.5 mM NaHCO 3 , 0.1 mM Ro-20-1724, 0.5 U/ml adenosine deaminase, and 1 mM IBMX), cells were treated with isoproterenol in HEM buffer for 5 min. After two more washes with HEM buffer, cells were harvested in 0.5% Triton X-100 containing 1 mM IBMX. The amount of cAMP was measured with the Direct Cyclic AMP Enzyme Immunoassay kit (Assay Designs Inc.).
ERK MAPK assay
The p44/42 MAP kinase assay was performed using a kit from Cell Signaling Technology as described previously (Wan et al, 1996) . Whole-cell lysates were prepared from MEF, Ga s
, or b-arrestin 1 À/À 2 À/À fibroblast cells. Cells were either treated or not with isoproterenol for 5 min. A monoclonal antibody to the phospho-p44/42 ERK MAPK (crosslinked to agarose beads) was added to immunoprecipitate the active ERK MAPK from cell lysates. Substrates (200 mM ATP and 2 mg GST-Elk-1 fusion protein) were added and the reaction was allowed to proceed at 301C for 30 min. After SDS-PAGE, the ERK MAPK activity (the phosphorylation of GST-Elk-1 by ERK MAPK) was measured by Western blotting with an anti-phospho-Elk-1 antibody (Cell Signaling Technology). In some experiments, cells were treated with 100 ng/ml PTX overnight. The intensity of the bands on the films from ERK kinase assays was scanned with a densitometer (KODAK). The data fitting was performed with GraphPad Prism.
Radio-ligand receptor binding assay
The radio-ligand binding assay was performed as described previously (January et al, 1997) . Membrane preparations were incubated with [ 3 H]CGP-12177 (100 nM) in the absence and presence of 1 mM terbutaline (to define nonspecific binding) in 25 mM Tris-HCl buffer (pH 7.4 at 371C) containing 154 mM NaCl. Incubation was carried out at 371C for 120 min, which was found to be optimal for specific binding. Incubations were performed in triplicate. The incubation was terminated by rapid vacuum filtration through GF/C glass-fiber filters. Each filter was rapidly washed with 3 Â 5 ml ice-cold 25 mM Tris-HCl buffer (pH 7.4). The filters were counted.
Cellular Src activation assay
The in vivo Src activation assay was performed as described previously (Wan et al, 1996) . MEF, Ga s À/À , and b-arrestin 1
cells were challenged with or without 10 mM isoproterenol for 5 min after serum starvation for 16 h. Cells were harvested in lysis buffer (40 mM Hepes, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% dodecyl-b-Dmaltoside (DoDM), 2 mM Na 3 VO 4 , 10mg/ml leupeptin, 1 mg/ml pepstatin A, and 0.2 mM PMSF). One microgram of anti-c-Src (B12 from Santa Cruz) antibody together with cell lysate containing 1.8 mg protein in 1 ml was incubated at 41C for 2 h before 20 ml of protein A/G agarose beads was added. After overnight incubation at 41C, the beads were spun down and washed twice with lysis buffer. After two more washes with kinase buffer (40 mM Hepes, pH 7.5, 5 mM MnCl 2 , 1 mM MgCl 2 , and 1 mM DTT), the beads were mixed with 45 ml kinase buffer containing 5 mg GST-CDB3 and 5 mCi [g-32 P]ATP and incubated at 301C for 30 min. The reaction was terminated by adding SDS loading buffer. After incubation at 951C for 5 min, GST-CDB3 was separated on a 7% SDS-PAGE gel, dried, and autoradiographed. In some experiments, cells were treated with 100 ng/ml PTX overnight before isoproterenol stimulation.
In vitro binding assay
The in vitro binding assay was performed as described previously (Ma and Huang, 1998; Lowry et al, 2002) . Eight micrograms of GST or GST fusion proteins and 2.5 mg c-Src together with 20 ml 50% glutathione agarose were incubated in 0.5 ml ice-cold binding buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 10 mM EDTA, 1 mg/ml BSA, and 0.1% NP-40) at 41C overnight. For phosphorylation-dependent bindings, 8 mg GST or GST fusion proteins and 2.5 mg c-Src together with 1 mM ATP were incubated in 50 ml kinase buffer (20 mM Hepes, pH 7.4, 5 mM MgCl 2 , 5 mM MnCl 2 ) at 301C for 30 min. The reaction was stopped by adding 450 ml ice-cold binding buffer and 20 ml 50% glutathione agarose and incubated at 41C overnight. The beads were washed three times with 1 ml washing buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 10 mM EDTA, and 0.1% NP-40). The protein complex was eluted with elution buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 10 mM EDTA, 10 mM glutathione, and 0.1% NP-40) and detected by anti-c-Src antibody (B12, Santa Cruz Biotechnology).
Protein purification
Human b 2 -AR protein was purified as described previously (Kobilka, 1995) . Purification of c-Src proteins was described before (Ma et al, 2000) . Purification of Ga s protein was as previously described with some modifications (Ma et al, 2000) . Briefly, pGEX 6P-Ga s plasmid was transformed into the bacterial strain BL21(DE3). One liter of bacterial culture was grown at room temperature until the absorbance at 600 nm was B1. Ga s protein expression was induced with 0.5 mM IPTG for 18 h at room temperature. The bacterial pellet was resuspended in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1 mg/ml lysozyme, and 0.2 mM PMSF) and incubated on ice for 30 min. After sonication, the lysate was spun down at 10 000 g for 2 h at 41C. Glutathione agarose resin (0.5 ml, from Sigma) was added to the supernatant after pre-equilibration of the resin with lysis buffer. The mixture was gently agitated at 41C for 3 h. After washing three times with 10 ml washing buffer (50 mM Tris, pH 8.0, 100 mM NaCl, and 0.2 mM PMSF), GST-tagged Ga s was eluted with 0.5 ml elution buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, and 10% glycerol). preScission protease (Amersham Biosciences) was used to cleave GST at 41C overnight.
Purification of Gbg proteins was as previously described with some modifications (Lowry et al, 2002) . After infection (for 72 h) with recombinant baculoviruses encoding Gb 1 and Gg 2 , the pellet from 1 l Hi5 cells was resuspended in 50 ml lysis buffer (50 mM Tris, pH 8.0, 1 mM EDTA, and protease inhibitors: 10 mg/ml leupeptin, 1 mg/ml pepstatin A, 1 mM benzamidine, and 0.2 mM PMSF). After sonication, the lysate was spun down at 150 000 g for 90 min at 41C. The membrane pellet was homogenized in 50 ml lysis buffer. After centrifugation, the pellet was resuspended in 50 ml extraction buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 2% DoDM, and protease inhibitors). After spining at 10 000 g for 2 h at 41C, 1 ml Ni-NTA agarose pre-equilibrated with extraction buffer was added to the supernatant. The mixture was gently agitated at 41C overnight. After washing three times with 10 ml washing buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 5 mM imidazole, and 0.2 mM PMSF), Gbg proteins were eluted with 10 ml elution buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 10 mM EDTA, and 200 mM imidazole).
Direct activation of c-Src by b 2 -AR
A 125 ng portion of c-Src and 1 mg b 2 -AR with 10 mM isoproterenol or 10 mM alprenolol in 24 ml kinase buffer (50 mM Hepes, pH 7.5, 10 mM MgCl 2 , 5 mM MnCl 2 , and 0.02% DoDM) were incubated on ice for 30 min. ATP (200 mM, final concentration) was added and the mixture was incubated at 301C for the time period indicated. The reaction was stopped by adding SDS sample loading buffer and incubated at 371C for 30 min. After 10% SDS-PAGE, anti-phosphotyrosine antibody was used to detect c-Src autophosphorylation.
[ 35 S]GTPcS loading assay
The [ 35 S]GTPgS loading assay was performed as described previously (Ma et al, 2000) . Ga s (20 nM), Gbg (1 mM), and b 2 -AR (30 nM) together with 10 mM alprenolol or isoproterenol in 200 ml loading buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 0.02% DoDM, and 5 mM GDP) were incubated on ice for 10 min. After incubation at 301C for 5 min, 100 nM [ 35 S]GTPgS was added. At various time points, 40 ml aliquots were moved into 1 ml ice-cold termination buffer (20 mM Tris, pH 8.0, 100 mM NaCl, and 25 mM MgCl 2 ) and loaded onto nitrocellulose membrane (Schleicher&Schuell BioScience). After three washes with 1 ml termination buffer, 4 ml scintillation solution was added to the membrane and 35 S was counted to measure GTPgS loading. GDP (5 mM) was used to determine the nonspecific binding.
